Simple jQuery Dropdowns
Please use this identifier to cite or link to this item: http://repository.li.mahidol.ac.th/dspace/handle/123456789/14895
Full metadata record
DC FieldValueLanguage
dc.contributor.authorP. Vejchapipaten_US
dc.contributor.authorS. Poomsawaten_US
dc.contributor.authorV. Chongsrisawaten_US
dc.contributor.authorS. Honsaweken_US
dc.contributor.authorY. Poovorawanen_US
dc.contributor.otherChulalongkorn Universityen_US
dc.contributor.otherMahidol Universityen_US
dc.date.accessioned2018-06-11T05:14:10Z-
dc.date.available2018-06-11T05:14:10Z-
dc.date.issued2012-03-28en_US
dc.identifier.citationEuropean Journal of Pediatric Surgery. Vol.22, No.1 (2012), 29-33en_US
dc.identifier.issn1439359Xen_US
dc.identifier.issn09397248en_US
dc.identifier.other2-s2.0-84858779026en_US
dc.identifier.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84858779026&origin=inwarden_US
dc.identifier.urihttp://repository.li.mahidol.ac.th/dspace/handle/123456789/14895-
dc.description.abstractIntroduction Biliary atresia (BA) is a fatal disease in children. Its main pathological feature is progressive immune-mediated cholangiopathy. Interleukin (IL)-12, IL-18, and interferon-gamma (IFN-gamma) play important roles in various immunological diseases. The objective was to investigate whether these serum markers were associated with clinical outcome in BA. Methods Serum levels of IL-12, IL-18, and IFN-gamma were determined using enzyme-linked immunosorbent assay from 46 BA patients (median age of 9 years) and 19 normal controls. The BA patients were then categorized into three groups according to their outcome: jaundice-free (29 cases), mild to moderate jaundice (10 cases), and marked jaundice (7 cases). The comparisons of serum IL-12, IL-18, and IFN-gamma levels among groups of the patients were performed using one-way analysis of variance with post-hoc tests. Data are expressed as mean + standard deviation. Results Serum IL-18 and IFN-gamma in BA patients were higher than the normal controls (IL-18: 113.3 + 82.6 vs. 80.5 + 9.9 pg/mL, p = 0.011 and IFN-gamma: 41.7 + 5.1 vs. 38.0 + 1.9 pg/mL, p < 0.001). There was no difference in serum IL-12 between BA and controls. Further analysis demonstrated that, in BA patients, only serum IL-18 levels significantly increased with the degree of jaundice (test for trend, p = 0.004). Conclusions Serum IL-18 and IFN-gamma levels were increased in medium-term survivors of BA. The elevated serum IL-18 in BA patients was associated with worse clinical outcome. These results suggest that IL-18 and IFN-gamma play roles in the pathophysiology of BA. Additionally, IL-18 is likely to be involved in the disease progression. Copyright © 2012 by Thieme Medical Publishers, Inc.en_US
dc.rightsMahidol Universityen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84858779026&origin=inwarden_US
dc.subjectMedicineen_US
dc.titleElevated serum IL-18 and interferon-gamma in medium-term survivors of biliary atresiaen_US
dc.typeArticleen_US
dc.rights.holderSCOPUSen_US
dc.identifier.doi10.1055/s-0032-1306260en_US
Appears in Collections:Scopus 2011-2015

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.